Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial

Kejing Tang, Fengying Wu, Fang Yang, Yu Yao, Yanqiu Zhao, Jianying Zhou, Ping Sun, Donglin Wang, Dongqing Lv, Huijie Wang, Yi Hu, Qiang Li, Yujiao Song, Grace Gao, Fang Pan, Archan Bhattacharya, Mahadi Baig, Patricia A. Lorenzini, Honeylet Wortman-Vayn, Trishala Agrawal, Caicun Zhou

Open source

DOI: 10.1097/cm9.0000000000004134
Published: 2026-05-26
Container: Chinese Medical Journal
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/cm9.0000000000004134,
  title = {Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial},
  author = {Kejing Tang and Fengying Wu and Fang Yang and Yu Yao and Yanqiu Zhao and Jianying Zhou and Ping Sun and Donglin Wang and Dongqing Lv and Huijie Wang and Yi Hu and Qiang Li and Yujiao Song and Grace Gao and Fang Pan and Archan Bhattacharya and Mahadi Baig and Patricia A. Lorenzini and Honeylet Wortman-Vayn and Trishala Agrawal and Caicun Zhou},
  year = {2026},
  journal = {Chinese Medical Journal},
  doi = {10.1097/cm9.0000000000004134},
  url = {https://doi.org/10.1097/cm9.0000000000004134}
}

RIS

TY  - JOUR
TI  - Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial
AU  - Kejing Tang
AU  - Fengying Wu
AU  - Fang Yang
AU  - Yu Yao
AU  - Yanqiu Zhao
AU  - Jianying Zhou
AU  - Ping Sun
AU  - Donglin Wang
AU  - Dongqing Lv
AU  - Huijie Wang
AU  - Yi Hu
AU  - Qiang Li
AU  - Yujiao Song
AU  - Grace Gao
AU  - Fang Pan
AU  - Archan Bhattacharya
AU  - Mahadi Baig
AU  - Patricia A. Lorenzini
AU  - Honeylet Wortman-Vayn
AU  - Trishala Agrawal
AU  - Caicun Zhou
PY  - 2026
JO  - Chinese Medical Journal
DO  - 10.1097/cm9.0000000000004134
UR  - https://doi.org/10.1097/cm9.0000000000004134
ER  -

APA

Tang, K., Wu, F., Yang, F., Yao, Y., Zhao, Y., Zhou, J., Sun, P., Wang, D., Lv, D., Wang, H., Hu, Y., Li, Q., Song, Y., Gao, G., Pan, F., Bhattacharya, A., Baig, M., Lorenzini, P. A., Wortman-Vayn, H., Agrawal, T., & Zhou, C. (2026). Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial. Chinese Medical Journal. https://doi.org/10.1097/cm9.0000000000004134

Source records

crossref · retrieved 2026-09-26T11:49:47.674Z